Sinopharm Group Co. Ltd (X2S) — Cash Flow Quality Index
Sinopharm Group Co. Ltd (X2S) has a Cash Flow Quality Index of -1.05x as of June 2023. Operating cash flow of €-2.63 Billion is below net income of €2.51 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore X2S cash flow metrics to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Sinopharm Group Co. Ltd Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Sinopharm Group Co. Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how aggressively does Sinopharm Group Co. Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Sinopharm Group Co. Ltd (2013–2025)
Year-by-year earnings quality comparison for Sinopharm Group Co. Ltd. For live market cap and the full company financial profile, see Sinopharm Group Co. Ltd market capitalisation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.98x | €14.14 Billion | €7.16 Billion | ▲ +20.6% |
| 2024 | 1.64x | €11.55 Billion | €7.05 Billion | ▼ -13.7% |
| 2023 | 1.90x | €17.17 Billion | €9.05 Billion | ▼ -22.9% |
| 2022 | 2.46x | €20.96 Billion | €8.53 Billion | ▲ +105.0% |
| 2021 | 1.20x | €9.31 Billion | €7.76 Billion | ▼ -22.7% |
| 2020 | 1.55x | €11.15 Billion | €7.19 Billion | ▼ -48.3% |
| 2019 | 3.00x | €18.78 Billion | €6.25 Billion | ▲ +379.7% |
| 2018 | 0.63x | €3.65 Billion | €5.84 Billion | ▲ +8.8% |
| 2017 | 0.58x | €3.21 Billion | €5.58 Billion | ▼ -71.1% |
| 2016 | 1.99x | €9.26 Billion | €4.65 Billion | ▼ -44.0% |
| 2015 | 3.56x | €13.41 Billion | €3.77 Billion | ▲ +83.8% |
| 2014 | 1.93x | €5.56 Billion | €2.87 Billion | ▼ -11.9% |
| 2013 | 2.20x | €4.94 Billion | €2.25 Billion | — |